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iPSC technologyAbstract Alzheimer’s disease (AD) remains to be a grand challenge for the international commu-
nity despite over a century of exploration. A key factor likely accounting for such a situation is the
vast heterogeneity in the disease etiology, which involves very complex and divergent pathways.
Therefore, intervention strategies shall be tailored for subgroups of AD patients. Both demographic
and in-depth information is needed for patient stratification. The demographic information includes
primarily APOE genotype, age, gender, education, environmental exposure, life style, and medical
history, whereas in-depth information stems from genome sequencing, brain imaging, peripheral
biomarkers, and even functional assays on neurons derived from patient-specific induced pluripo-
tent cells (iPSCs). Comprehensive information collection, better understanding of the disease mech-
anisms, and diversified strategies of drug development would help with more effective intervention
in the foreseeable future.Introduction
Alzheimer’s disease (AD) is one of the leading causes of death
in senior people. Caring for AD patients with deteriorating
cognitive and daily functions poses a great economic and psy-
chological burden for the families as well as society. Initially
discovered in 1906, the pathological hallmarks of AD, namely
amyloid plaques and neurofibrillary tangles, have been well
documented over a century. However, little had been known
about the disease mechanisms at molecular level until the iden-
tification of the gene encoding amyloid precursor proteinnces and
290 Genomics Proteomics Bioinformatics 14 (2016) 289–297(APP) and the genetic mutations causing familial AD [1,2].
Nonetheless, familial AD only constitutes 2% of AD
patients [3], while the vast majority of AD cases are not caused
by the genetic mutations affecting the coding or processing of
APP. For sporadic AD, the molecular pathogenesis seems to
be far from understood as yet.
Up till now, only four drugs have been approved for AD
treatment by the Food and Drug Administration (FDA) in
USA and its counterparts in Europe [4]. These drugs target
neural transmission and are all used for symptom relief,
sometimes even with unbearable side effects. They are unable
to modify the disease trajectory, not even slowing down the
disease progression. Therefore, the ‘‘neural transmission”
hypothesis for AD has not been well supported by the human
trials, and deficiency in neural transmission may merely be a
downstream and symptomatic problem in AD. In the past cou-
ple of decades, most of the efforts on drug development have
been devoted to the clearance of amyloid or the aggregating
oligomers, which is believed to be a major causal factor
according to the ‘‘amyloid cascade hypothesis” [5]. Although
recent studies targeting amyloid showed marginal progress in
the early stage AD [6,7], most of the clinical trials along this
line have been very disappointing. Beyond amyloid clearance,
other prevention or treatment strategies have also been initi-
ated with no conclusive evidence of success so far [8].
To achieve more positive outcome, better patient stratifica-
tion shall be adopted in the future based on comprehensive
collection of patient information. The details will be discussed
in the following sections (Figure 1).Figure 1 Path from patient stratification to personalized intervention
Collection of demographic information is the basis for patient stratific
the design of personalized intervention. AD, Alzheimer’s disease; iPSC
particulate matter (62.5 lm).Demographic information for AD
Currently, the well-recognized demographic information about
AD includes APOE genotype, age, gender, education, environ-
mental exposure, life style, and medical history.
APOE genotype
APOE e4 allele is the major genetic risk of sporadic AD, which
confers risks 3–4 folds higher for people carrying one e4 allele
and 10 folds higher for peoples carrying two e4 alleles com-
pared to non-carriers [2]. Although mainly viewed as a gene
involved in the lipid metabolism pathway, APOE seems to
be associated with many AD-related processes. Most notably,
APOE is involved in amyloid b (Ab) metabolism and amyloid
clearance [9]. APOE may also be involved in brain develop-
ment. For example, infants carrying APOE e4 allele have dif-
ferent brain structure compared to non-carriers [10]. The
altered brain structures at early developmental stage may con-
fer susceptibility for AD at the old age. APOE e4 genotype is
also associated with reduced glucose metabolism in the brain
independent of amyloid aggregation [11]. Since deficiency in
energy metabolism is considered as one of the major upstream
factors in AD pathogenesis, this study suggests that APOE
genotype itself can be a causal factor for AD. Thus, AD
patients with 0, 1, or 2 e4 alleles may follow different paths
to the disease stage and therefore shall be treated differently.
Due to the critical roles of APOE in the development offor AD
ation. Incorporation of in-depth information will greatly facilitate
, induced pluripotent stem cell; CSF, cerebrospinal fluid; PM 2.5,
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attempted, and notably drugs targeting APOE have demon-
strated efficiency in mouse model of AD [12].Age
Apart from APOE, age is the most recognized risk factor for
sporadic AD. Sporadic AD mostly starts after the age of 65,
while the chance of developing AD climbs to 40% for peo-
ple aged over 85 [13]. Aging is accompanied by the systematic
deterioration of the condition over the whole body. Most
notably, brain perfusion (blood supply to the whole brain)
continues to decline starting at the age of 22, which is likely
the root cause of many problems due to the critical role of
energy supply in brain functions. Studies have shown that
brain atrophy and amyloid deposition are part of the normal
aging process. Even in normal elderly people without demen-
tia, over 1/3 has amyloid plaque in the brain [14]. In addition,
brain transcriptome studies showed that the aging brain is
characterized by up-regulation of immune response and
down-regulation of synaptic transmission, which is similar
to the gene dysregulation pattern in AD [15]. To some extent,
AD can be viewed as accelerated aging. Interestingly, aging is
lately considered by some people as a treatable disease and
anti-aging clinical trials have been proposed [16].Gender
Epidemiological studies suggest that females have a higher risk
of developing AD than males do [17], although the exact rea-
son remains unclear at this moment. It has been postulated
that decreased estrogen levels at old age may be partially
responsible for higher incidence of AD in females [18]. Estro-
gen is neuroprotective and estrogen receptor b plays a critical
role in brain function [19]. Studies on the human brain tran-
scriptome have also shown that immune response is more
widely spread in aged female brains than aged male brains,
consistent with the accelerated aging scenario in female brains
[20]. There is interaction between gender and APOE in both
brain connection and cerebrospinal fluid (CSF) markers [21],
which may be partially attributed to the involvement of both
estrogen receptor b and APOE in certain brain functions. Fur-
ther elucidation of the gender risk of AD may require better
understanding of the brain network through ongoing big brain
projects worldwide.Education
Lower education level is associated with higher risk of develop-
ing AD [22]. Education process is accompanied by sophisti-
cated brain wiring. Lower education likely leads to less
complex brain network which is more susceptible for break-
down, which is the so-called ‘‘brain reserve” hypothesis [23].
However, it has also been reported that the rate of cognitive
decline is higher for people with higher education once AD
is diagnosed [24]. This is likely due to the depletion of ‘‘brain
reserve” after the onset of AD symptoms even for people with
higher education.Environmental exposure
Exposure to non-healthy environment is also associated
with higher risk of developing AD. For example, long-term
exposure to high concentration of fine particulate matter
(62.5 lm) environment can lead to peripheral biomarker
change linked to AD [25]. Mechanistic studies have shown that
similar environment can lead to elevated inflammation and
AD pathologies in mice [26]. Additionally, high concentration
of pesticide, such as dichlorodiphenyldichloroethylene (DDE),
in the blood is also associated with higher AD risk [27]. Over-
all, environmental exposure may affect the brain either directly
through the inhalation process or indirectly through the
blood–brain barrier [25].Life style
Life style can have major effects on the risk of developing AD.
Cigarette smoking and alcohol drinking are associated with
higher risk, both of which may disrupt the global metabolism
and in the meantime exert epigenetic modification in the brain
[28]. On the other hand, more active lifestyle, such as physical
exercise [29], social communication, and brain stimulating
activities like music and arts [30], has a protective effect. The
beneficial effect may arise from better energy supply and more
synaptic activities.Medical history
Certain medical histories are associated with elevated AD risk.
For instance, hypertension is associated with both vascular
dementia and AD [31], which is consistent with the critical role
of the cardiovascular system and energy supply in AD devel-
opment. In a population-based study over 25 years, late-life
atrial fibrillation was found to be the highest risk of AD
among several heart diseases examined [32]. In another longi-
tudinal study, the duration of type 2 diabetes was found to be a
risk factor for AD [33]. In addition, periodontal disease is also
associated with higher risk of AD through increased brain
amyloid load [34]. In a meta-analysis over studies on the rela-
tionship between bacterial infection and AD, certain bacterial
infection such as by Chlamydophila pneumoniae was found to
increase the risk of 4–10 fold, likely through sustained high
level of immune response [35]. Notably sleep has been recently
linked to AD because of its role in amyloid clearance [36,37],
and sleep postures may affect efficiency in amyloid removal
[38].In-depth information for AD
Demographic information alone is insufficient to achieve pre-
cise assessment of AD patients, which would be greatly facili-
tated by collecting in-depth information including genome,
brain imaging, and peripheral biomarkers. In addition, recent
development in induced pluripotent stem cell (iPSC) technol-
ogy makes it possible to conduct functional assays on
patient-derived neurons.
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Although APOE e4 allele confers high risk of developing AD,
it is neither necessary nor sufficient for AD development [39].
For instance, some people without APOE e4 alleles can
develop AD, while others carrying one or two APOE e4 alleles
may never develop AD throughout their lives. Genome-wide
association studies (GWAS) have revealed 20 additional risk
loci such as those encoding clusterin (CLU) and bridging inte-
grator 1 (BIN1), all with moderate risk [40]. A recent work
showed that marginally-significant SNPs (P< 103) from
GWAS studies may contribute significantly to the prediction
of genetic risk of AD [41]. Other than the genetic risk from
common variations examined in GWAS studies, rare varia-
tions detected by sequencing technologies may also confer risk
of AD. For instance, rare variations in genes encoding trigger-
ing receptor expressed on myeloid cells 2 (TREM2) [42] and
phospholipase D family, member 3 (PLD3) [43] from exome
sequencing studies could significantly increase the risk of
developing AD, albeit limited to a small population of the rare
variant carriers. The relative contribution from common and
rare variations is still under debate, which could be tackled
using whole-genome sequencing (WGS) since compared to
GWAS, WGS can detect both common and rare variations
once sufficient sequencing depth is reached.
Brain imaging
Brain imaging offers the direct measurement of the patients’
brain structure or function. The degree of brain atrophy can
be evaluated by magnetic resonance imaging (MRI). Glucose
uptake as an indicator of energy metabolism level can be mea-
sured by 18F-fluorodeoxiglucouse positron emission tomogra-
phy (PET). For more specific diagnosis of AD, various PET
technologies such as Pittsburgh compound B (PIB) have been
developed for the measurement of Ab amyloid [44] and tangle
[45,46]. PET and MRI have also been combined to elucidate
the causal relationship between amyloid deposition and regio-
nal cerebral blood flow [47].
Peripheral biomarkers
Brain imaging is currently not suitable for early diagnosis due
to its poor accessibility especially in China. Therefore, periph-
eral biomarkers from CSF, blood, urine [48], and saliva [49]
are highly desirable. Most notably, low level of Ab42 and high
level of p-tau in CSF have been demonstrated to be sensitive
biomarkers for AD diagnosis [50]. Aside from these well-
recognized biomarkers, other biomarkers, mostly in the
peripheral blood, have also been investigated. For example,
the expression levels of several microRNAs including miR-
15a in the blood are associated with AD [51]. Lower expression
level of ribosome genes has also been reported in the blood of
AD patients [52]. Apart from gene expression, the level of
immune-related proteins or analytes in the plasma or serum
has also been associated with AD. For example, complement
C3 has been replicated in independent studies [53]. A panel
of 21 serum proteins has also been replicated in independent
sample sets [54]. A panel of blood analytes including pancre-
atic polypeptide (PPY) shows high correlation with brain amy-
loid load [55]. In addition, a protein microarray studyidentified a panel of 20 autoantibodies with high accuracy in
discriminating AD from control [56]. A multi-tissue study
showed that calpain activity is increased in CSF and decreased
in blood of AD patients [57]. Interestingly, a rare study of
telomere in buccal cells showed shorter telomeres and
increased number of telomeres in AD patients compared to
controls [58].
Functional assays on patient-derived neurons
The most relevant cell type for AD studies is neuron, which is
not accessible in patients. Notably, the development of iPSC
technology opens the door to examine patient-specific neurons
derived from the skin fibroblast. Various assays can be con-
ducted on these neurons. For instance, Ab42/Ab40 ratio and
gene expression profiles were compared on iPSC-derived neu-
ral progenitor cells from PSEN1 mutation carriers and con-
trols [59]. A PSEN1 DE9 mutation was shown to specifically
affect the c-secretase activity of PSEN1 [60]. Neurotoxicity
caused by various forms of Ab can be examined too [61].
Moreover, these neurons can also be used to test whether
drugs like c-secretase modulators are effective in reversing cer-
tain cellular phenotypes [62]. In the past few years, 3D culture
models have been under development, which may better model
the 3D neuronal network in vitro [63].
Intervention strategies for AD
Although there are limited options available for treating AD,
proper intervention as discussed in this section is highly recom-
mended. Prevention is the best medicine [64]. Therefore, it is a
common view to treat the disease at its early stage, with or
without medication.
Physical activity
The effect of physical exercises on AD has been extensively
studied in both human and mouse models, with the beneficial
effect reported at different stages of AD. For example, regular
physical exercises can lower the rate of conversion from mild
cognitive impairment (MCI) to dementia [65]. The exact mech-
anism underlying such beneficial effect is likely very complex.
Obviously, exercise can improve the cardiovascular functions
and provide better blood supply to the brain, whereas at the
molecular level, it may involve elevated level of BDNF in the
serum [66]. Interestingly, conventional exercises such as Tai-
Chi have also been demonstrated to confer a wide spectrum
of beneficial effects [67].Brain stimulation
Proper brain stimulation such as music is protective for AD. It
may help maintain existing neural networks or develop new
ones [68]. Music and arts are the common approaches for
brain stimulation. Studies showed that certain sound waves
may help clear amyloid from the blood stream [69]. In addi-
tion, non-invasive stimulations such as transcranial magnetic
stimulation can improve cognition [70]. To restore certain neu-
ronal circuits in patients with confirmed neurodegeneration,
invasive deep brain stimulation has been tested in AD and
Table 1 Stage-specific intervention strategies for AD
Note: AD, Alzheimer’s disease; Ab, Amyloid beta; EOAD, early-onset
Alzheimer’s disease; APOE, apolipoprotein E; iPSC, induced
pluripotent stem cell.
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sive operation, some minimally invasive brain stimulation
approaches are also currently under development [72].
Social communication
Social communication can improve cognitive function for AD
patients. Active cognitive life style such as social engagement
has been shown to be associated with reduced risk of develop-
ing AD [73], whereas elderly people living a solitary life tend to
have higher risk of developing depression [74], which is associ-
ated with higher risk of AD [75]. Thus, engaging elderly people
in community activities is strongly recommended.
Diet
Western diet is associated with higher risk of developing AD,
while Mediterranean diet is protective [76,77]. Moreover,
Mediterranean diet and physical activity are independently
protective for AD [29]. The Mediterranean diet likely favors
a stronger cardiovascular system which can provide better
energy and nutrient supply to the brain. In addition, dietary
supplements have also been widely studied. For example,
omega3 has been shown by many studies to slow down cogni-
tive decline [78] and consumption of cocoa flavanol can
improve cognitive function [79]. Other than these supplements,
Selenium as an anti-aging nutrient is also widely studied in the
field of aging and AD [80].
Drugs
The four FDA-approved drugs for AD mainly target synaptic
stimulation. In the past few years, the most actively pursued
drug development for AD is Ab immunotherapy that targets
the clearance of amyloid plaques or Ab oligomers [6]. Along
the same line, targeting the pathological processing of Ab
has also been pursued, mainly focusing on c-secretase [81].
Tau, another major hallmark of AD, is also an actively-
pursued drug target [82]. Clinical trials for drugs targeting c-
secretase or tau have not been successful so far [83,84]. While
these drugs target specific molecules, Chinese traditional med-
icine likely has broader impact on the brain and the body as a
whole. For example, some of the widely-used Chinese tradi-
tional medicine for AD such as ginseng can stimulate blood
flow in the brain [85], while some traditional Chinese medicine
may also enhance amyloid clearance [86].
Stage-specific intervention strategy for AD
Based on current findings, we here summarize a stage-specific
intervention strategy for AD [87,88]. Please note that some of
the intervention approaches may be applicable to other stages
as well (Table 1).
Preimplantation stage
Intervention at the preimplantation stage is highly controver-
sial due to the ethical issues. Currently, preimplantation
diagnosis is only available for families with inheritable diseases
[89], including familiar AD. It is foreseeable that genomeediting may be used to correct the causal mutations in familiar
AD in the future. However, genome editing is not yet a mature
technology for clinical practice at this moment due to the con-
cerns including off-targeting. In addition, the ethical issue in
human germline genome editing is extremely sensitive due to
the risk of ‘‘playing God” by some people.
Childhood, youth, and adulthood
Proactive prevention could be performed at stages of child-
hood, youth, and adulthood. This is particularly important
for people who carry APOE e4 allele or other high risk genetic
variations. A good lifelong education can also help build a
resilient brain network [24]. Furthermore, it is necessary to
avoid non-healthy living and working environment. It is
equally important to stick to a healthy diet and stay away from
bad habits such as cigarette smoking and alcohol drinking.
MCI and preclinical AD
With confirmed diagnosis from cognitive tests, peripheral
biomarkers, or brain imaging, proper intervention shall be
applied for MCI and preclinical AD. A good starting point
is to have regular physical exercise. This can be supplemented
with brain stimulating activities such as music and arts. Early
stage patients should be actively involved in social communica-
tion with family, friends, or local community. Certain Chinese
traditional medicine may also be helpful [86]. In addition, iPSC
technology may be needed to properly design personalized
treatment approaches.
Mild AD
Once the patients progress to the clinical AD stage, medical
intervention shall be added on top of the non-medical treat-
ments described above. Several factors shall be taken into
account for such intervention, including neural transmission,
energy supply, and amyloid clearance. While prescribed drugs
can stimulate neural transmission, nutritional supplements
294 Genomics Proteomics Bioinformatics 14 (2016) 289–297such as coenzyme Q10 may provide more energy supply to the
brain [90]. Furthermore, the most heavily invested Ab
immunotherapy can remove the pathological amyloid buildup
[6].
Moderate AD
At the moderate AD stage, neural inflammation caused by
prolonged stimulation by amyloid deposit may be a more
pressing issue to deal with [91]. AD brain and blood transcrip-
tome studies suggest that elevated level of the innate immune
system may be a suitable target for further drug development
[92]. For example, glucogon-like peptide 1 analogs, the
widely-studied neuro-protective agent, are involved in
reducing neural inflammation among many other protective
functions [93]. More studies directly targeting neural inflam-
mation including with non-steroidal anti-inflammatory drugs
are underway [94].
Severe AD
At the late stage of the disease, neuronal cell death becomes a
major issue [95]. Neuronal cell death results in the permanent
breakdown of the brain network, which is responsible for cog-
nitive and daily functions. Thus, neural regeneration therapy
could be more effective for patients at this stage. Interestingly,
a recent study demonstrated enhanced learning and memory in
AD mice after transplantation of inhibitory interneuron pro-
genitors in the brain [96]. Stem cell technology will likely play
an increasingly important role in neural regeneration. In addi-
tion to stem cell transplantation, activation of endogenous
neural stem cells or converting the inflammatory astrocytes
to neurons are other viable options [97]. However, these stud-
ies are still at the preclinical stages and the efficacy on human
AD is thus unknown as yet.
Concluding remarks
Although convergent AD symptoms have been observed, the
underlying heterogeneous pathways for AD development
require personalized intervention strategy. Adjustment of life
styles may be a lifelong battle especially for those who carry
causal mutations for familial AD or high risk genetic varia-
tions for sporadic AD. The combination of proper education,
diet, life style, and environment seems to be the best prescrip-
tion to prevent or delay the onset of AD. For patients at the
early stage of the disease, physical and mental exercises, social
communication, and traditional Chinese medicine could be
effective to slow down the disease progression. For patients
at the mild or moderate clinical AD stage, medical interven-
tions, including those targeting neural transmission, energy
supply, Ab aggregation, and neural inflammation, should
come into play. For patients at the severe stage with consider-
able loss of neurons, neural regeneration therapy could be crit-
ical to restore the normal function of the brain, although
clinical trials have not been reported.
At each of the disease stages, intervention can be further
tailored toward the patients according to the demographic
and in-depth information described in this review. For exam-
ple, drugs especially APOE-targeting drugs may act differentlyin patients with different APOE genotypes. As more drugs
become available, it may be necessary to test the drug effi-
ciency on patients with different genotypes. For such kind of
test, patient-derived neurons can be used for preliminary tests.
Other than the demographic and genetic factors, brain imaging
and peripheral biomarkers may also be employed for patient
stratification. In addition, age factor shall be considered when
designing programs of physical activities because some activi-
ties may not be suitable for the highly-aged patients. For
elderly females, hormone replacement therapy may be benefi-
cial as well. Furthermore, for people with specific medical con-
ditions such as hypertension or type 2 diabetes, management
of these specific medical conditions is good for both AD pre-
vention and treatment.Competing interest
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